Xiang Wang

机构：Xuzhou Medical College, First Affiliated Hospital of Guangdong Pharmaceutical University, Xuzhou Central Hospital

发表论文 11 篇 · 总被引 114 次 · h-index 5

代表论文

• Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial (2024 · The Lancet Respiratory Medicine · 被引 42)
• Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study (2024 · European Journal of Cancer · 被引 10)
• Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer. (2025 · Journal of Clinical Oncology · 被引 9)
• Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study. (2024 · Journal of Clinical Oncology · 被引 7)
• Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study (2025 · European Journal of Cancer · 被引 3)
• KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis (2025 · BMC Cancer · 被引 1)